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Atypical Presentation of Allergic Bronchopulmonary Aspergillosis: An Unusual Case of Undiagnosed Bronchial Asthma Christopher Gordon, DO, and Sean P. Brady, MD; University at Buffalo, Buffalo, NY. RATIONALE: Allergic Bronchopulmonary Aspergillosis (ABPA) is caused by a hypersensitivity reaction to Apergillus fumigatus. Presentation includes wheezing, expectoration of brownish mucus plugs, pulmonary opacities and/or central bronchiectasis on chest imaging. ABPA in patients without previously diagnosed asthma or cystic fibrosis is a rare occurrence. Here we present an adult female with ABPA and undiagnosed asthma. METHODS: CT scan of chest, serological evaluation, immediate hypersensitivity skin test, and methacholine challenge were performed. RESULTS: 56-year-old woman developed dyspnea and expectoration of brownish mucus plugs. She failed multiple rounds of oral antibiotics. CT chest showed bilateral infiltrates, air trapping at the bases and dense consolidation of the left upper lobe. Subsequent bronchoscopy noted copious mucus and removal of mucus plugs. BAL showed significant fungal element, suspicious for aspergillus. Evaluation showed positive skin testing to Aspergillus fumigatus, total IgE level of 5839 IU/mL, negative aspergillus IgG. Eosinophil count peaked at 1120 cells/L. She completed 12 weeks of high dose oral steroids with symptom resolution. Follow-up CT of the chest showed complete resolution of airspace consolidation. IgE level dropped to 395 IU/mL. She sustained 3 recurrences, manifesting with IgE >2900 IU/mL and symptom recurrence. She was successfully treated with oral steroids and oral antifungal medication. Baseline pulmonary function testing was negative for obstruction or reversibility. However, methacholine challenge was positive after dose 0.25 mg/mL. CONCLUSIONS: This is an exceptionally rare case of atypical ABPA with lack of severe asthma and/or cystic fibrosis. Diagnosis in this scenario is difficult but vital for early recognition and treatment to prevent future morbidity. ) is the most common contact allergen, and sensitization can cause joint replacement failure. The immune signature of nickel sensitization includes expansion of Vb17 T cells, and HLADR52c is the MHC restriction element for one human Ni 2+ reactive T cell clone. We hypothesized that other HLA variants might associate with nickel sensitization in patients with joint replacement failure. METHODS: Subjects enrolled in an IRB approved study were recruited: 1) failed implant: n58 nickel sensitized, n58 non-nickel sensitized; 2) preoperative: n58 nickel sensitized, n55 non-nickel sensitized. Nickel sensitization was diagnosed by nickel patch test (n513/16), and/or Ni 2+ LPT (n515/16). Genomic DNA from peripheral blood was extracted using a QIAamp DNA Mini-Kit, and HLA-DR typing was performed by PCR-sequence specific primers high resolution methods (ClinImmune Labs). RESULTS: Over half the subjects (n516/29) were HLA-DR53+, 10 were HLA-DR53-, and 4 had an HLA-DR53 null allele (DRB4*01:03:01:02N), of whom one was also positive for HLA-DR53. Nickel sensitization was similarly distributed in preoperative patients irrespective of HLA-DR53 (62.5% and 60% respectively). Among postoperative patients with joint failure, nickel sensitization associated with HLA-DR53 (75% DR53+ were nickel allergic, vs. 25% DR53-, p50.13). Overall, 69% of nickel allergic patients were DR53+, vs. 31% of non-nickel sensitized patients, and no patient with a null allele was sensitized to nickel (p50.0134). CONCLUSIONS: Nickel sensitized patients with joint failure are more likely to be HLA-DR53+, compared to those without nickel allergy. The DR53 allele may be more efficient at presenting nickel in the presence of a hardware source of nickel antigens.
